Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Chris Markoch

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.

Vertex will pay $85 per share in cash for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Vertex expects to finance the acquisition using a combination of cash on hand and debt.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.